Literature DB >> 26796599

Current Status and Development of Vaccines and Other Biologics for Human Rabies Prevention.

Charles E Rupprecht1, Thirumeni Nagarajan2, Hildegund Ertl3.   

Abstract

Rabies is a neglected viral zoonosis with the highest case fatality of any infectious disease. Pasteur's historical accomplishments during the late 19(th) century began the process of human vaccine development, continuing to evolve into the 21(st) century. Over the past 35 years, great improvements occurred in the production of potent tissue culture vaccines and the gradual removal from the market of unsafe nerve tissue products. Timely and appropriate administration of modern biologics virtually assures survivorship, even after severe exposures. Nevertheless, in the developing world, if not provided for free nationally, the cost of a single course of human prophylaxis exceeds the average monthly wage of the common worker. Beyond traditional approaches, recombinant, sub-unit and other novel methods are underway to improve the availability of safe, effective and more affordable rabies biologics.

Entities:  

Keywords:  encephalitis; lyssavirus; neglected tropical disease; prophylaxis; rabies; vaccination; virus; zoonosis

Mesh:

Substances:

Year:  2016        PMID: 26796599     DOI: 10.1586/14760584.2016.1140040

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  9 in total

Review 1.  Rhabdoviruses as vectors for vaccines and therapeutics.

Authors:  Gabrielle Scher; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2020-10-29       Impact factor: 7.090

2.  First case of Stevens-Johnson syndrome after rabies vaccination.

Authors:  Li Ma; Xusheng Du; Yu Dong; Lirong Peng; Xiaonian Han; Jianhua Lyu; Hehe Bai
Journal:  Br J Clin Pharmacol       Date:  2018-02-09       Impact factor: 4.335

3.  Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study.

Authors:  Ravish H S; Akash Khobragade; Durga Satapathy; Monica Gupta; Surendra Kumar; Vinay Bhomia; Ramasubramanian V; Maharshi Desai; Ashok Dilipkumar Agrawal
Journal:  Hum Vaccin Immunother       Date:  2021-09-09       Impact factor: 4.526

4.  Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice.

Authors:  Jung-Eun Park; Hyun-Jin Shin
Journal:  Vet Q       Date:  2021-12       Impact factor: 3.320

Review 5.  Lyssaviruses and rabies: current conundrums, concerns, contradictions and controversies.

Authors:  Charles Rupprecht; Ivan Kuzmin; Francois Meslin
Journal:  F1000Res       Date:  2017-02-23

6.  Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity.

Authors:  Catherine Yankowski; Christoph Wirblich; Drishya Kurup; Matthias J Schnell
Journal:  NPJ Vaccines       Date:  2022-09-23       Impact factor: 9.399

Review 7.  Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?

Authors:  Wei Zhan; Manish Muhuri; Phillip W L Tai; Guangping Gao
Journal:  Front Immunol       Date:  2021-05-11       Impact factor: 7.561

8.  An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs.

Authors:  Margit Schnee; Annette B Vogel; Daniel Voss; Benjamin Petsch; Patrick Baumhof; Thomas Kramps; Lothar Stitz
Journal:  PLoS Negl Trop Dis       Date:  2016-06-23

Review 9.  The Route of Administration of Rabies Vaccines: Comparing the Data.

Authors:  Deborah J Briggs; Susan M Moore
Journal:  Viruses       Date:  2021-06-27       Impact factor: 5.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.